Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Krsnaa Diagnostics Limited ( (IN:KRSNAA) ) has provided an update.
Krsnaa Diagnostics has moved to overhaul its leadership structure, with the board approving the appointment of Raju Venkatraman and Lilian Jessie Paul as additional independent directors for a two-year term, and reappointing Chetan Desai as an independent director for a further five years. These changes, which are subject to shareholder approval, are intended to deepen the board’s entrepreneurial, operational and governance expertise and strengthen committee leadership.
The company also named Chandra Prakash Singh as interim chief financial officer and key managerial personnel with immediate effect, ensuring continuity in financial oversight until a permanent CFO is appointed. At the same time, the tenures of whole-time director Pallavi Bhatevara and independent directors Rajiva Ranjan Verma and Chhaya Palrecha will conclude in late April 2026, marking a significant board reshuffle that could influence strategic direction and governance for stakeholders.
More about Krsnaa Diagnostics Limited
Krsnaa Diagnostics Limited operates in the medical diagnostics and healthcare services industry, providing imaging and pathology services across India. The company focuses on affordable, high-volume diagnostic solutions, often through public-private partnerships and network-based models aimed at expanding access to healthcare diagnostics.
Average Trading Volume: 4,826
Technical Sentiment Signal: Sell
Current Market Cap: 19.6B INR
Find detailed analytics on KRSNAA stock on TipRanks’ Stock Analysis page.